

## THIS ISSUE'S AUTHORS

**ROBERT K. BROONER, Ph.D.**, is professor of medical psychology at Johns Hopkins University (JHU) in Baltimore, and he directs JHU's Addiction Treatment Services at Bayview Medical Center. He has worked in the field of behavioral science and substance abuse for 20 years and has published extensively in research areas including alcoholism, injection drug abuse, multiple diagnoses in drug abusers, and the use of incentives in drug abuse treatment.

**TONY P. GEORGE, M.D.**, is assistant professor of psychiatry at Yale University School of Medicine and director of the Dual Diagnosis and Smoking Research Program at the Connecticut Mental Health Center. His research has focused on the effects of abused drugs on clinical and cognitive function in patients with chronic mental illness.

**T. RON JACKSON, M.S.W.**, is executive director of Evergreen Treatment Services and affiliate associate professor in the School of Social Work, University of Washington, Seattle. He has worked as a clinician, administrator, researcher, and educator in addiction treatment, specializing in opiate dependence, since 1972.

**MICHAEL KIDORE, Ph.D.**, is associate professor in psychiatry and behavioral sciences at JHU, as well as associate director of JHU's Addiction Treatment Services at Bayview Medical Center. His research interests and publications include the subjects of methadone maintenance therapy, psychiatric and substance use comorbidity, and contingent rewards in outpatient drug abuse treatment programs.

**THOMAS R. KOSTEN, M.D.**, is professor of psychiatry at Yale University School of Medicine and chief of psychiatry for the VA Connecticut Healthcare System. His

major research area has been psychopharmacology of medications used to treat cocaine abuse. Some of his studies focus on psychiatric disorders in substance abusers and on the neurobiology of substance dependence.

**CARMEN L. MASSON, Ph.D.**, assistant adjunct professor at the University of California, San Francisco, has focused her research on behavioral interventions designed to reduce risky behaviors linked with HIV and other infectious diseases among drug-dependent individuals. Her research interests also include the role of cofactors such as homelessness and psychiatric conditions in the ability of drug abusers to engage in preventive health behaviors.

**OLGA V. PARKER, Ph.D.**, is clinical director at CODA, the largest alcohol and drug treatment agency in Portland, Oregon. Dr. Parker has worked in substance abuse treatment for 17 years and as a psychotherapist for more than 20 years.

**DAVID C. PERLMAN, M.D.**, is professor of medicine at Albert Einstein College of Medicine and director of the AIDS inpatient unit at Beth Israel Medical Center in New York. His research interests focus on the infectious complications of HIV and substance abuse, and on strategies to deliver care to drug users.

**JAMES L. SORENSEN, Ph.D.**, is adjunct professor of psychiatry at the University of California, San Francisco (UCSF), and a co-principal investigator for the UCSF Treatment Research Center. Over the past 20 years, he has developed and evaluated a community network approach to drug abuse treatment, assessed the efficacy of family therapy for methadone maintenance patients, and tested the efficacy

of small-group HIV education in three drug abuse treatment modalities.

**ANN S. UHLER, M.A.**, is executive director of CODA, Inc., in Portland, Oregon. Ms. Uhler has more than 25 years' experience in the substance abuse field, and she is a certified practitioner of psychodrama, sociometry, and group psychotherapy. Ms. Uhler is a provider representative on NIDA's National Drug Abuse Treatment Clinical Trials Network.

## &amp; PANEL RESPONDENTS

**JANELLE BLAKE, CAC III**, is a clinician with Denver's Addiction Research and Treatment Services who specializes in treatment of HIV-infected substance-abusing patients.

**TOM BREWSTER, M.S.W.**, is executive director of Addiction Research and Treatment Services, an agency providing services to approximately 1,500 clients. He is associate professor in psychiatry, University of Colorado School of Medicine, and has more than 30 years' experience in substance abuse treatment and research activities.

**R. LORRAINE COLLINS, Ph.D.**, is senior research scientist, Research Institute on Addictions, University at Buffalo, State University of New York. Her research interests include prevention and treatment of addictions, cognitive factors in alcohol use and abuse, alcohol and violence, and psychosocial issues as they relate to substance use and misuse.

**WILLIAM CORNELLY, M.H.S.**, is vice president of research and development at Fresh Start, Inc., in Philadelphia. Fresh Start is a residential, comprehensive, addiction-

recovery care-management organization that participates in NIDA's Clinical Trials Network. Mr. Cornely also has served as clinical director at various inpatient and intensive outpatient treatment programs in the Philadelphia area.

**MARLA CORWIN, L.C.S.W., CAC III**, is clinical services coordinator for Addiction Research and Treatment Services in Denver, with extensive experience in direct clinical care for adults and working with the specialty populations of HIV-infected substance abusers and patients involved in the child welfare system

**ERIC ENNIS, L.C.S.W., CAC III**, is instructor of psychiatry and the director of adult outpatient services for Addiction Research and Treatment Services in Denver. Mr. Ennis oversees five community-based clinic sites for ARTS in the Denver Metro area, including specialized programs for women, HIV-infected substance abusers, offenders, and opioid-dependent patients.

**OLIVIA ESTEP, B.S.N., R.N., CAC III**, is clinic coordinator, outpatient women's treatment services for Addiction Research

and Treatment Services in Denver. The program has innovative components and enhancements designed to attract women with substance abuse problems and retain them in treatment.

**CHRIS FARENTINOS, M.D.**, is clinical director and co-owner of ChangePoint Inc., which participates in two ongoing research projects: NIDA's Clinical Trials Network and the Practice-Research Collaboratives funded by the Center for Substance Abuse Treatment. Dr. Farentinos has been in the alcohol and drug abuse field for 13 years and was recently appointed as adjunct faculty for the Oregon Health Sciences University School of Public Health and Preventive Medicine.

**CHRISTINE GRELLA, Ph.D.**, is associate research psychologist at the UCLA Integrated Substance Abuse Programs, Neuropsychiatric Institute. Dr. Grella has conducted field-based treatment outcome studies within both mental health and substance abuse treatment settings, using both experimental and naturalistic research designs. Her research has focused on treat-

ment processes and outcomes, with an emphasis on special populations.

**DARIA LESLEA, L.P.N., CAC II**, is nurse, clinician, and clinical supervisor at the Addiction Research and Treatment Services Outpatient Clinic in Denver. She works with opioid-dependent patients and is special liaison for local social services departments.

**SCOTT POWERS, M.S.W., CAC III**, is clinic coordinator for the Addiction Research and Treatment Services CrossPoint Program in Denver, a specialized outpatient clinic for State and Federal offenders with substance abuse problems.

**DOUGLAS ZIEDONIS, M.D., M.P.H.**, is director of the Division of Addiction Psychiatry and associate professor with tenure at the Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey. Dr. Ziedonis is a principal investigator for the Mercer Trenton Addiction Science Center, part of the Delaware Valley Node of NIDA's Clinical Trials Network.